HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Charlotta Enerbäck Selected Research

S100 Calcium Binding Protein A7

4/2017Overexpression of Psoriasin (S100A7) Contributes to Dysregulated Differentiation in Psoriasis.
7/2012Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation.
1/2012The expression of Psoriasin (S100A7) and CD24 is linked and related to the differentiation of mammary epithelial cells.
11/2007S100A7 (Psoriasin), highly expressed in ductal carcinoma in situ (DCIS), is regulated by IFN-gamma in mammary epithelial cells.
12/2005A putative role for psoriasin in breast tumor progression.
9/2005Psoriasin (S100A7) and calgranulin-B (S100A9) induction is dependent on reactive oxygen species and is downregulated by Bcl-2 and antioxidants.
1/2002Psoriasin expression in mammary epithelial cells in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Charlotta Enerbäck Research Topics

Disease

22Psoriasis (Pustulosis Palmaris et Plantaris)
02/2024 - 01/2002
7Neoplasms (Cancer)
08/2014 - 01/2002
6Noninfiltrating Intraductal Carcinoma (DCIS)
07/2012 - 01/2002
5Breast Neoplasms (Breast Cancer)
02/2013 - 01/2002
4Melanoma (Melanoma, Malignant)
08/2014 - 06/2007
3Inflammation (Inflammations)
01/2021 - 09/2013
2Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 11/2011
1Psoriatic Arthritis
01/2021
1Genetic Risk Score
01/2017
1Infections
06/2014
1Lymphatic Metastasis
02/2013
1Crohn Disease (Crohn's Disease)
12/2012
1Rheumatoid Arthritis
12/2012
1Arthritis (Polyarthritis)
11/2011
1Metabolic Syndrome (Dysmetabolic Syndrome X)
11/2011
1Dihydropyrimidine Dehydrogenase Deficiency
02/2010
1Neuroblastoma
07/2008
1Skin Diseases (Skin Disease)
11/2007
1Hypoxia (Hypoxemia)
12/2005

Drug/Important Bio-Agent (IBA)

7S100 Calcium Binding Protein A7IBA
04/2017 - 01/2002
5Proteins (Proteins, Gene)FDA Link
01/2019 - 09/2005
4CytokinesIBA
01/2021 - 11/2007
4Biomarkers (Surrogate Marker)IBA
01/2018 - 11/2011
3InflammasomesIBA
01/2021 - 07/2012
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2012 - 12/2005
2Interleukin-17 (Interleukin 17)IBA
01/2021 - 01/2019
2Interleukin-22 (IL-22)IBA
01/2019 - 06/2014
2Genetic Markers (Genetic Marker)IBA
10/2018 - 03/2014
2ChemokinesIBA
09/2013 - 11/2011
2Calcium-Binding ProteinsIBA
07/2012 - 01/2012
2Calgranulin BIBA
11/2007 - 09/2005
2Messenger RNA (mRNA)IBA
12/2005 - 01/2002
2Estrogen ReceptorsIBA
12/2005 - 01/2002
1Interleukin-18 (Interleukin 18)IBA
01/2021
1Interleukin-23 (Interleukin 23)IBA
01/2021
1Imiquimod (Aldara)FDA LinkGeneric
01/2021
1Interleukin-17 ReceptorsIBA
01/2019
1Keratins (Keratin)IBA
01/2019
1Differentiation AntigensIBA
01/2019
1InterferonsIBA
01/2017
1P-2 (P 2)IBA
01/2017
1HLA-C Antigens (HLA-C)IBA
12/2015
1DNA (Deoxyribonucleic Acid)IBA
08/2014
1InterleukinsIBA
09/2013
1RNA Polymerase II (RNA Polymerase B)IBA
02/2013
1fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA
02/2013
1HydrolasesIBA
02/2013
1Small Interfering RNA (siRNA)IBA
07/2012
1NeuropeptidesIBA
11/2011
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
11/2011
1Fluorouracil (Carac)FDA LinkGeneric
02/2010
1OligonucleotidesIBA
07/2008
1Calgranulin AIBA
11/2007
1Cyclin-Dependent Kinase Inhibitor p16IBA
06/2007
1Reactive Oxygen Species (Oxygen Radicals)IBA
12/2005
1Monoclonal AntibodiesIBA
01/2002

Therapy/Procedure

2Therapeutics
01/2021 - 09/2013
1Drug Prescriptions
02/2024
1Ligation
08/2014